Constellation Pharmaceuticals Inc CNST
We take great care to ensure that the data presented and summarized in this overview for CONSTELLATION PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CNST
Top Purchases
Top Sells
About CNST
Insider Transactions at CNST
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 15
2021
|
James E Audia |
SELL
Sale (or disposition) back to the issuer
|
Direct |
25,434
-100.0%
|
-
|
|
Jul 15
2021
|
Mark A Goldsmith |
SELL
Sale (or disposition) back to the issuer
|
Direct |
89,857
-100.0%
|
-
|
|
Jul 15
2021
|
Jigar Raythatha |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,961
-100.0%
|
-
|
|
Mar 04
2021
|
Mark A Goldsmith |
BUY
Exercise of conversion of derivative security
|
Direct |
14,987
+50.0%
|
-
|
|
Feb 22
2021
|
Emma Reeve Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,260
-100.0%
|
$231,620
$37.6 P/Share
|
|
Feb 22
2021
|
Emma Reeve Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,260
+50.0%
|
$50,080
$8.04 P/Share
|
|
Feb 19
2021
|
Emma Reeve Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,010
-100.0%
|
$148,370
$37.71 P/Share
|
|
Feb 19
2021
|
Emma Reeve Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,010
+50.0%
|
$32,080
$8.04 P/Share
|
|
Feb 18
2021
|
Emma Reeve Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,100
-100.0%
|
$40,700
$37.58 P/Share
|
|
Feb 18
2021
|
Emma Reeve Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,100
+50.0%
|
$8,800
$8.04 P/Share
|
|
Feb 17
2021
|
Emma Reeve Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
410
-100.0%
|
$15,170
$37.56 P/Share
|
|
Feb 17
2021
|
Emma Reeve Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
410
+50.0%
|
$3,280
$8.04 P/Share
|
|
Feb 17
2021
|
Column Group L P > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,000
-9.16%
|
$720,000
$36.95 P/Share
|
|
Jan 19
2021
|
Karen Valentine |
SELL
Open market or private sale
|
Direct |
17,203
-55.18%
|
$567,699
$33.96 P/Share
|
|
Jan 19
2021
|
Karen Valentine |
BUY
Exercise of conversion of derivative security
|
Direct |
17,203
+50.0%
|
$189,233
$11.5 P/Share
|
|
Dec 21
2020
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Indirect |
4,020
-2.81%
|
$140,700
$35.02 P/Share
|
|
Dec 21
2020
|
Emma Reeve Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,720
-100.0%
|
$200,200
$35.11 P/Share
|
|
Dec 21
2020
|
Emma Reeve Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,720
+47.13%
|
$40,040
$7.11 P/Share
|
|
Dec 14
2020
|
Column Group L P > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
60,214
+1.15%
|
$60,214
$1.55 P/Share
|
|
Mar 20
2020
|
Column Group L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
5,539
+0.09%
|
$127,397
$23.15 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders